Browse POLB

Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Cytoplasmic in normal conditions. Translocates to the nucleus following DNA damage.
Domain PF14792 DNA polymerase beta palm
PF14791 DNA polymerase beta thumb
PF10391 Fingers domain of DNA polymerase lambda
PF14716 Helix-hairpin-helix domain
Function

Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases.

> Gene Ontology
 
Biological Process GO:0002200 somatic diversification of immune receptors
GO:0002377 immunoglobulin production
GO:0002440 production of molecular mediator of immune response
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002566 somatic diversification of immune receptors via somatic mutation
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006266 DNA ligation
GO:0006284 base-excision repair
GO:0006286 base-excision repair, base-free sugar-phosphate removal
GO:0006287 base-excision repair, gap-filling
GO:0006288 base-excision repair, DNA ligation
GO:0006290 pyrimidine dimer repair
GO:0006310 DNA recombination
GO:0007431 salivary gland development
GO:0007435 salivary gland morphogenesis
GO:0007568 aging
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009314 response to radiation
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0016311 dephosphorylation
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016446 somatic hypermutation of immunoglobulin genes
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0022612 gland morphogenesis
GO:0033151 V(D)J recombination
GO:0033152 immunoglobulin V(D)J recombination
GO:0035272 exocrine system development
GO:0036296 response to increased oxygen levels
GO:0045471 response to ethanol
GO:0048535 lymph node development
GO:0048536 spleen development
GO:0048732 gland development
GO:0048872 homeostasis of number of cells
GO:0051103 DNA ligation involved in DNA repair
GO:0051402 neuron apoptotic process
GO:0055093 response to hyperoxia
GO:0070482 response to oxygen levels
GO:0070997 neuron death
GO:0071707 immunoglobulin heavy chain V-D-J recombination
GO:0071897 DNA biosynthetic process
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097305 response to alcohol
GO:0098501 polynucleotide dephosphorylation
GO:0098502 DNA dephosphorylation
Molecular Function GO:0003684 damaged DNA binding
GO:0003887 DNA-directed DNA polymerase activity
GO:0003906 DNA-(apurinic or apyrimidinic site) lyase activity
GO:0004518 nuclease activity
GO:0004519 endonuclease activity
GO:0004520 endodeoxyribonuclease activity
GO:0004536 deoxyribonuclease activity
GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0016779 nucleotidyltransferase activity
GO:0016829 lyase activity
GO:0016835 carbon-oxygen lyase activity
GO:0034061 DNA polymerase activity
Cellular Component GO:0005819 spindle
GO:0005874 microtubule
GO:0005876 spindle microtubule
> KEGG and Reactome Pathway
 
KEGG hsa03410 Base excision repair
Reactome R-HSA-5649702: APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
R-HSA-73930: Abasic sugar-phosphate removal via the single-nucleotide replacement pathway
R-HSA-73884: Base Excision Repair
R-HSA-73894: DNA Repair
R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-5651801: PCNA-Dependent Long Patch Base Excision Repair
R-HSA-110362: POLB-Dependent Long Patch Base Excision Repair
R-HSA-597592: Post-translational protein modification
R-HSA-110373: Resolution of AP sites via the multiple-nucleotide patch replacement pathway
R-HSA-110381: Resolution of AP sites via the single-nucleotide replacement pathway
R-HSA-73933: Resolution of Abasic Sites (AP sites)
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between POLB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of POLB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of POLB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6690.0213
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3990.846
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8660.57
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2660.454
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0490.974
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6610.729
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0510.894
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2550.862
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.170.917
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1030.936
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1690.931
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1180.237
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of POLB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of POLB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of POLB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by POLB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of POLB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of POLB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between POLB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPOLB
Namepolymerase (DNA directed), beta
Aliases DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location8p12-p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting POLB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting POLB.
ID Name Drug Type Targets #Targets
DB00987CytarabineSmall MoleculePOLB1
DB01592IronSmall MoleculeAHSP, CP, EGLN1, FEN1, FTH1, FXN, HBA1, HDAC8, NEIL1, NEIL2, POLB, ......13
DB03222dATPSmall MoleculePOLB1
DB07479(1S)-1,2,3,4-TETRAHYDRO-BENZO[C]PHENANTHRENE-2,3,4-TRIOLSmall MoleculePOLB1